Redefining Early Phase Clinical Services

[Pages:2]Redefining Early Phase Clinical Services

The Syneos HealthTM cutting edge Miami Phase I/IIa Translational Medicine Unit is located within a broad and vibrant community of dynamic healthcare providers, researchers, patient populations and study volunteers.

Building upon years of Early Phase Development experience and reliable operations, the Miami clinical unit complements our Global Phase I offering and presents a strategic option for Phase I/IIa conduct within the United States.

? HAL, Withdrawal

? CNS Center of Excellence

? QTc/Telemetry ? FIH

? Simplified Reg Process (IRB only)

? 43% R&D Tax Refund

? Japanese Bridging

? Biosimilars

Toronto

84 Beds

APAC

In-Hospital Units

Quebec

248 Beds

Miami

44 Beds

? BE/BA/505b2 ? Biosimilars ? Clin Pharm, FIH ? Large Panels ? Intense PK ? QTc/Telemetry ? On-site Bio Lab

? FIH ? Renal/Hepatic ? In-patient Center

of Excellence ? Telemetry

With its focus on First-in-Human, SAD-MAD, In-Patient and Proof-of-Concept studies, the Syneos Health Miami clinical unit benefits from the positive recruitment dynamics of south Florida. Through a carefully maintained network of collaborators in close proximity to our unit, our unique Phase I Patient Access Models provide strong access to distinct patient populations, as well as therapeutically aligned expertise, medical technologies and procedures.

By selecting Miami for their Phase I program, our clients benefit from the same quality, service and support that Syneos Health has exhibited for more than 20 years.

With our innovative approach to Phase I patient recruitment, cutting-edge facilities across four global locations, two industry-leading bioanalytical laboratories and therapeutically-aligned expertise, Syneos Health provides tailor-made solutions that deliver better, smarter, faster ways to bring

? 2018 Syneos HealthTM. All rights reserved.

Recruitment of Specialized Patients and Populations

Not all inclusive ? Allergy ? Alzheimer's ? Asthma ? Cold/Flu ? COPD ? Diabetes (T2DM) ? Hepatic impaired ? HIV/Hep B/Hep C* ? Healthy elderly ? Hyperlipidemia ? Hypertension ? Hypogonadal ? NASH/NAFLD ? Obesity ? Osteoarthritis ? Parkinson's* ? Recreational drug user ? Renal impaired ? Rheumatoid arthritis

Study Types Available in Miami

? First in Human ? Proof-of-Concept ? Phase I in-patient ? SAD/MAD ? Biosimilars ? Translational medicine ? Cardiac safety ? PK/PD ? Safety/Tolerability ? Drug-interaction ? Food effects

*In development

biopharmaceutical therapies to life.

Phase I/IIa Translational Medicine Unit Miami, Florida

Quick Facts ? Located in the University of Miami Life Sciences and Technology Park ? Diverse Miami-Dade County population of more than 2.5 million ? Extensive network of collaborators and six local hospitals ? 44 inpatient beds, 23,000 sq. ft. clinic with additional ground floor recruitment and screening center ? Broad access to patients, special populations and healthy volunteers ? Two bioanalytical labs in North America for sample analysis ? In-house pharmacy facilities offering aseptic techniques as well as non-sterile compounding for drug preparation

Contact Us Today

rmation@

Syneos Health ? Info: MiamiClinic-Qtr1/2018

About Syneos Health

Syneos HealthTM (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies ? INC Research and inVentiv Health ? we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit .

? 2018 Syneos HealthTM. All rights reserved.

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download